PT -期刊文章盟Vignan Yogendrakumar盟——列昂尼德•Churilov盟——彼得·J·米切尔AU - Timothy J Kleinig盟Nawaf Yassi AU -文森特Thijs AU -泰迪吴盟沾光沙非盟-彼得·贝利盟-海伦M杜威盟-菲利普MC崔AU -马爱丽丝盟Tissa韦杰云盟盟-卡洛斯Garcia-Esperon盟杰弗里- Ronil诉钱德拉盟丹尼斯·约翰Cordato AU -伯纳德燕DMedSc盟选手Gagan Sharma盟马克W帕森斯-帕特里夏·米德斯蒙德盟盟——杰弗里·艾伦唐南盟——斯蒂芬·M·戴维斯盟——布鲁斯·c·v·坎贝尔Tenecteplase TI -安全性和有效性和溶栓串联病变患者中风:因果分析的EXTEND-IA秋明石油公司- 10.1212 / WNL试验援助。0000000000207138 DP - 2023年3月06 TA -神经病首页学PG - 10.1212 / WNL。0000000000207138 4099 - http://n.首页neurology.org/content/early/2023/03/06/WNL.0000000000207138.short 4100 - //www.ez-admanager.com/content/early/2023/03/06/WNL.0000000000207138.full AB -背景和目的:的安全性和有效性tenecteplase串联病变患者中风是未知的。我们进行了比较分析tenecteplase和串联病变患者溶栓。方法:我们首先比较tenecteplase的治疗效果和患者的溶栓串联使用个别患者病变EXTEND-IA秋明石油公司的数据试验。我们在初始评估颅内再灌注血管造影评估和90天的夫人序数物流和弗斯回归模型。因为两个关键结果,死亡率和症状性颅内出血,很少在收到那些溶栓EXTEND-IA秋明石油公司试验,我们生成的混合估计这些结果通过补充试验数据估计入射通过荟萃分析研究确定在系统回顾。然后计算未经调整的风险差异比较集中发病率估计对于那些接受溶栓试验中观察到的那些接收tenecteplase。结果:483名患者(15%)的七十一年EXTEND-IA秋明石油公司试验具有串联病变。病变患者,观察颅内再灌注在11/56(20%)的tenecteplase治疗患者与1/15(7%)患者溶栓治疗(优势比:2.19;95%置信区间:0.28—-17.29)。观察无显著差异在90天的夫人(常见或调整:1.48; 95% CI: 0.44-5.00). A pooled study-level proportion of alteplase associated mortality and symptomatic intracranial hemorrhage was 0.14 (95% CI: 0.08-0.21) and 0.09 (95% CI: 0.04-0.16), respectively. Compared to a mortality rate of 0.09 (95% CI: 0.03-0.20) and a symptomatic intracranial hemorrhage rate of 0.07 (95% CI: 0.02-0.17) in tenecteplase treated patients, no significant difference was observed.Conclusions: Functional outcomes, mortality, and symptomatic intracranial hemorrhage did not significantly differ between tenecteplase and alteplase treated tandem lesion patients.Classification of Evidence: This study provides Class III evidence that tenecteplase is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and symptomatic intracranial hemorrhage compared with alteplase, in patients with acute stroke due to tandem lesions. However, the confidence intervals do not rule out clinically important differences.